Literature DB >> 20153263

A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.

Akihiko Yokoyama1, Min Lin, Alpana Naresh, Issay Kitabayashi, Michael L Cleary.   

Abstract

AF4 and ENL family proteins are frequently fused with MLL, and they comprise a higher order complex (designated AEP) containing the P-TEFb transcription elongation factor. Here, we show that AEP is normally recruited to MLL-target chromatin to facilitate transcription. In contrast, MLL oncoproteins fused with AEP components constitutively form MLL/AEP hybrid complexes to cause sustained target gene expression, which leads to transformation of hematopoietic progenitors. Furthermore, MLL-AF6, an MLL fusion with a cytoplasmic protein, does not form such hybrid complexes, but nevertheless constitutively recruits AEP to target chromatin via unknown alternative mechanisms. Thus, AEP recruitment is an integral part of both physiological and pathological MLL-dependent transcriptional pathways. Bypass of its normal recruitment mechanisms is the strategy most frequently used by MLL oncoproteins. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153263      PMCID: PMC2824033          DOI: 10.1016/j.ccr.2009.12.040

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  58 in total

1.  A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.

Authors:  J F DiMartino; T Miller; P M Ayton; T Landewe; J L Hess; M L Cleary; A Shilatifard
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.

Authors:  Chi Wai So; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

3.  The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.

Authors:  Jorge F DiMartino; Paul M Ayton; Everett H Chen; Clarissa C Naftzger; Bryan D Young; Michael L Cleary
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.

Authors:  C Lavau; C Du; M Thirman; N Zeleznik-Le
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

5.  MLL targets SET domain methyltransferase activity to Hox gene promoters.

Authors:  Thomas A Milne; Scott D Briggs; Hugh W Brock; Mary Ellen Martin; Denise Gibbs; C David Allis; Jay L Hess
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

6.  Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with Af9 after chromosomal translocation in leukemia.

Authors:  Emma C Collins; Alexandre Appert; Linda Ariza-McNaughton; Richard Pannell; Yoshihiro Yamada; Terence H Rabbitts
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

7.  LAF4, an AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia.

Authors:  Anne R M von Bergh; H Berna Beverloo; Paul Rombout; Elisabeth R van Wering; Margreet H van Weel; Geoffrey C Beverstock; Philip M Kluin; Rosalyn M Slater; Ed Schuuring
Journal:  Genes Chromosomes Cancer       Date:  2002-09       Impact factor: 5.006

Review 8.  Molecular genetics of human leukemias: new insights into therapy.

Authors:  D Gary Gilliland
Journal:  Semin Hematol       Date:  2002-10       Impact factor: 3.851

9.  Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation.

Authors:  Amy S Weinmann; Peggy J Farnham
Journal:  Methods       Date:  2002-01       Impact factor: 3.608

10.  Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties.

Authors:  Akihiko Yokoyama; Issay Kitabayashi; Paul M Ayton; Michael L Cleary; Misao Ohki
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

View more
  181 in total

Review 1.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.

Authors:  Ali Shilatifard
Journal:  Annu Rev Biochem       Date:  2012       Impact factor: 23.643

2.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 3.  RNA polymerase II elongation control.

Authors:  Qiang Zhou; Tiandao Li; David H Price
Journal:  Annu Rev Biochem       Date:  2012-03-09       Impact factor: 23.643

Review 4.  Trithorax group proteins: switching genes on and keeping them active.

Authors:  Bernd Schuettengruber; Anne-Marie Martinez; Nicola Iovino; Giacomo Cavalli
Journal:  Nat Rev Mol Cell Biol       Date:  2011-11-23       Impact factor: 94.444

5.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.

Authors:  Man Mohan; Chengqi Lin; Erin Guest; Ali Shilatifard
Journal:  Nat Rev Cancer       Date:  2010-09-16       Impact factor: 60.716

6.  Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6.

Authors:  Michaela Liedtke; Paul M Ayton; Tim C P Somervaille; Kevin S Smith; Michael L Cleary
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

Review 7.  The upstreams and downstreams of H3K79 methylation by DOT1L.

Authors:  Hanneke Vlaming; Fred van Leeuwen
Journal:  Chromosoma       Date:  2016-01-04       Impact factor: 4.316

8.  Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Authors:  Chenxi Shen; Stephanie Y Jo; Chenzhong Liao; Jay L Hess; Zaneta Nikolovska-Coleska
Journal:  J Biol Chem       Date:  2013-09-01       Impact factor: 5.157

9.  The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Authors:  Shan Lin; Roger T Luo; Mahesh Shrestha; Michael J Thirman; James C Mulloy
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

10.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.